1. Outcomes of hypertrophic cardiomyopathy in Japanese children: a retrospective cohort study.
- Author
-
Mori, Hiroki, Yoshikawa, Tadahiro, Kimura, Hitomi, Ono, Hiroshi, Kato, Hitoshi, Ono, Yasuo, Nii, Masaki, Shindo, Takahiro, Inuzuka, Ryo, Horigome, Hitoshi, Miura, Masaru, Hirono, Keiichi, Kobayashi, Tomio, Kogaki, Shigetoyo, Furutani, Yoshiyuki, and Nakanishi, Toshio
- Subjects
HYPERTROPHIC cardiomyopathy ,JAPANESE people ,HEART failure ,HEART transplant recipients ,CHILD patients ,COHORT analysis - Abstract
There has been no multicenter study on the prognosis of pediatric hypertrophic cardiomyopathy (HCM) in Japan. Therefore, we conducted a retrospective multicenter observational study on the long-term survival rate in patients diagnosed with HCM under the age of 18 between 1990 and 2014. Twenty institutions participated. A total of 180 patients were identified. The median age at diagnosis was 5.8 years old and median duration of observation was 8.3 years. Although six patients (3%) deteriorated into the dilated phase of HCM, no patient received heart transplantation. Freedom from death at 1, 5, 10, and 20 years were 97%, 92%, 84%, and 80%, respectively. There were 26 deaths. Among them, 11 patients died suddenly, presumably due to arrhythmia, and 15 patients died of heart failure. The presence of heart failure symptoms and a greater cardiothoracic ratio were significant risk factors for heart failure-related death. There were no significant risk factors identified for arrhythmia-related death. In conclusion, the prognosis of pediatric HCM in Japan is good and similar to those reported in population-based studies in the United States and Australia. Significant risk factors for heart failure-related death were identified in pediatric patients with HCM in Japan. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF